Jupiter Neurosciences, Inc. (NASDAQ:JUNS) Sees Significant Decline in Short Interest

Jupiter Neurosciences, Inc. (NASDAQ:JUNS) saw a significant drop in short interest in the month of August. As of August 14th, there was short interest totaling 29,679 shares, a drop of 85.5% from the July 30th total of 205,218 shares. Currently, 6.3% of the shares of the stock are sold short. Based on an average trading volume of 85,940 shares, the days-to-cover ratio is currently 0.3 days.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Wall Street Zen upgraded Jupiter Neurosciences from a “strong sell” rating to a “sell” rating in a research report on Sunday, August 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jupiter Neurosciences in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

Institutional Investors Weigh In On Jupiter Neurosciences

Several hedge funds have recently bought and sold shares of JUNS. Allen Capital Group LLC acquired a new position in shares of Jupiter Neurosciences in the 4th quarter valued at $31,000. Yorkville Advisors Global LP bought a new position in Jupiter Neurosciences during the fourth quarter worth about $135,000. Geode Capital Management LLC lifted its holdings in Jupiter Neurosciences by 27.8% during the fourth quarter. Geode Capital Management LLC now owns 132,641 shares of the company’s stock worth $135,000 after acquiring an additional 28,826 shares in the last quarter. Finally, Vestor Capital LLC grew its stake in Jupiter Neurosciences by 144,607.2% in the first quarter. Vestor Capital LLC now owns 970,985 shares of the company’s stock valued at $365,000 after acquiring an additional 970,314 shares during the period.

Jupiter Neurosciences Price Performance

Shares of Jupiter Neurosciences stock traded down $0.10 on Wednesday, hitting $5.08. 192,430 shares of the company’s stock traded hands, compared to its average volume of 406,862. Jupiter Neurosciences has a one year low of $4.56 and a one year high of $137.96. The stock has a market capitalization of $3.91 million, a PE ratio of -0.27 and a beta of 1.98. The firm’s 50-day moving average price is $11.23 and its two-hundred day moving average price is $22.97.

Jupiter Neurosciences (NASDAQ:JUNS) last posted its earnings results on Friday, August 14th. The company reported ($5.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.75) by ($1.31). The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.40 million.

Jupiter Neurosciences Company Profile

Jupiter Neurosciences, Inc, a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease.